OR
ORN.F Oryzon Genomics S.A
- Market cap
- EUR 206M
- P/E
- -
- P/B
- 1.62x
- ROE
- -2.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ORN.F undervalued?
Graham numberThe Graham number of Oryzon Genomics S.A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oryzon Genomics S.A fundamental analysis
No fundamental analysis for Oryzon Genomics S.A yet.
Oryzon Genomics S.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oryzon Genomics S.A
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS a…
Full company profileOryzon Genomics S.A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Oryzon Genomics S.A annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 735K | 16.8K | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 4.64M | 4.05M | 6.49M | - | 8.99M | 9.87M | 15.2M | 13.9M | 7.06M | 10.7M | - |
| Operating Income | -4.63M | -4.32M | -2.94M | -3.82M | -4.29M | -7.01M | -5.49M | -4.55M | -4.42M | -5.71M | -6.25M |
| EBITDA | - | -3.61M | -2.76M | -3.65M | -4.16M | -6.58M | -5.27M | -4.06M | -4.11M | -4.86M | -5.96M |
| Net Income | -5.45M | -5.20M | -1.18M | -3.68M | -3.40M | -4.69M | -4.23M | -3.35M | -3.58M | -2.61M | -2.74M |
| EPS | - | -0.16 | -0.03 | -0.08 | -0.06 | -0.09 | -0.08 | -0.06 | -0.06 | -0.03 | -0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 49.7M | 61.0M | 67.5M | 80.1M | 94.1M | 95.4M | 104M | 107M | 109M | 145M | 141M |
| Total Liabilities | 27.0M | 26.6M | 22.3M | 19.0M | 18.2M | 24.1M | 31.1M | 25.1M | 21.7M | 26.7M | 20.9M |
| Shareholders' Equity | 22.7M | 34.4M | 45.1M | 61.1M | 75.9M | 71.3M | 72.6M | 81.8M | 87.0M | 118M | 120M |
| Cash & Short-term Investments | 22.0M | 35.0M | 34.3M | 35.1M | 39.6M | 28.7M | 21.3M | 12.3M | 5.62M | 28.4M | 14.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.01M | -4.71M | -666K | -3.93M | -4.82M | -3.63M | -1.85M | -575K | -5.92M | -2.36M | - |
| Capital Expenditure | 4.32M | 105K | 170K | 115K | 153K | 175K | 75.6K | 14.5M | 8.02M | 11.0M | 0.00 |
| Free Cash Flow | - | -9.12M | -7.72M | -13.5M | -14.0M | -15.4M | -16.1M | -15.1M | -13.9M | -13.4M | - |
| Ratios | |||||||||||
| ROE | -24.0% | -15.1% | -2.6% | -6.0% | -4.5% | -6.6% | -5.8% | -4.1% | -4.1% | -2.2% | -2.3% |
| ROA | -11.0% | -8.5% | -1.7% | -4.6% | -3.6% | -4.9% | -4.1% | -3.1% | -3.3% | -1.8% | -1.9% |
| Net Profit Margin | -740.9% | -31,001.9% | - | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Oryzon Genomics S.A dividends
Oryzon Genomics S.A has not paid dividends in the last 9 fiscal years.
Who owns Oryzon Genomics S.A
- Insiders 20.97%
- Institutions 1.87%
- Public & others 77.16%
- Shares outstanding 82.0M
- Free float 64.9M
Oryzon Genomics S.A company profile
- Company name
- Oryzon Genomics S.A
- Ticker
- ORN.F
- ISIN
- ES0167733015
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 46
- Fiscal year end
- December
- Address
- Sant Ferran 74, Cornellà de Llobregat, Spain, 08940
- Phone
- 34 93 515 13 13
- Website
- oryzon.com
About Oryzon Genomics S.A
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
Oryzon Genomics S.A management
9- Dr. Carlos Manuel Buesa ArjolCo-Founder, Chairman, CEO & President
- Mr. Enric Rello CondominesCOO & CFO
- Mr. Jordi Xaus PeyScientific Director
- Mr. Xavier Perpinya RiberaHead of Internal Audit & Compliance
- Dr. Rolando Gutierrez-Esteinou M.D.Chief Medical Officer for CNS Programs · born 1962
- Mr. Augusto Pinel RubioSecretary
- Mr. Emili Torrell CortadaDirector of Business Development
- Ms. Neus Virgili BernadoDirector of Industrial Property
- Ms. Sonia Paloma Gutierrez BezonDirector of Clinical Operations